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ABSTRACT: Aminoacyl-tRNA synthetases (ARSs) are
ubiquitously expressed enzymes responsible for ligating
amino acids to cognate tRNAmolecules.Mutations in four
genes encoding an ARS have been implicated in inherited
peripheral neuropathy with an axonal pathology, suggest-
ing that all ARS genes are relevant candidates for disease
in patients with related phenotypes. Here, we present re-
sults from a mutation screen of the histidyl-tRNA syn-
thetase (HARS) gene in a large cohort of patients with
peripheral neuropathy. These efforts revealed a rare mis-
sense variant (c.410G>A/p.Arg137Gln) that resides at a
highly conserved amino acid, represents a loss-of-function
allele when evaluated in yeast complementation assays,
and is toxic to neurons when expressed in a worm model.
In addition to the patient with peripheral neuropathy,
p.Arg137Gln HARS was detected in three individuals by
genome-wide exome sequencing. These findings suggest
that HARS is the fifth ARS locus associated with axonal
peripheral neuropathy. Implications for identifying ARS
alleles in human populations and assessing them for a role
in neurodegenerative phenotypes are discussed.
Hum Mutat 34:191–199, 2013. C© 2012 Wiley Periodicals, Inc.
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Introduction
Peripheral neuropathies are a heterogeneous class of disorders
mainly characterized by distal motor and sensory dysfunction. Eti-
ological classifications for peripheral neuropathies include acquired,
syndromic, and inherited neuropathy, each of which can be further
subdivided into axonal or demyelinating forms [Dyck and Lam-
bert, 1968]. The prevalence of peripheral neuropathy can exceed
10% in aging populations, making this class of diseases a major
public healthcare concern in terms of proper diagnosis, progno-
sis, and therapeutic development [Martyn and Hughes, 1997]. The
prevalence andheterogeneity of peripheral neuropathies underscore
the importance of identifying genetic lesions that directly cause or
modify clinical phenotypes.
Aminoacyl-tRNA synthetases (ARSs) are ubiquitously expressed,
essential enzymes that perform the first step of protein translation—
attaching amino acids to cognate tRNA molecules [Antonellis and
Green, 2008]. Despite the ubiquitous function of ARSs, mutations
in four loci encoding an ARS enzyme have been implicated in dom-
inant and recessive peripheral neuropathies with an axonal pathol-
ogy: glycyl-tRNA synthetase (GARS; MIM# 600287), tyrosyl-tRNA
synthetase (YARS; MIM# 603623), alanyl-tRNA synthetase (AARS;
MIM# 601065), and lysyl-tRNA synthetase (KARS; MIM# 601421)
[Antonellis et al., 2003; Jordanova et al., 2006; Latour et al., 2010;
McLaughlin et al., 2010]. These data indicate that genes encoding
ARS enzymes are relevant candidates for disease in patients with pe-
ripheral neuropathy and no known contributing genetic variation.
The full complement of ARS loci and alleles implicated in periph-
eral neuropathy remains undefined. Addressing this issue will aid in
determining if peripheral nerve axons are susceptible tomutations in
a specific subset of ARS enzymes or if mutations in any ARS enzyme
will result in a peripheral neuropathy. Furthermore, the mecha-
nistic link between ARS mutations and neurodegeneration has not
been identified and many disease-associated alleles have not been
evaluated for neurotoxicity in vivo. Establishing an approach for
rapidly characterizing alleles in the 37 human ARS-encoding genes
will be critical for advancing our understanding of ARS-related
C© 2012 WILEY PERIODICALS, INC.
neurodegeneration. Here, we present data from patient-based mu-
tation screening, yeast complementation assays, and a wormmodel
of neurotoxicity that reveal a loss-of-function, neurotoxic histidyl-
tRNA synthetase (HARS) variant. Our findings raise the possibility
that HARS mutations are associated with axonal peripheral neu-
ropathy and further support a role for impaired tRNA charging in
the pathogenesis of ARS-related peripheral neuropathy.
Materials and Methods
HARSMutation Analysis
DNA samples were isolated from 363 patients diagnosed with
peripheral neuropathy by collaborating physicians. DNA samples
from the ClinSeqTM cohort were collected as previously described
[Biesecker et al., 2009]. The appropriate review boards of each par-
ticipating institution approved these studies. The HARS gene was
assessed for mutations at the NIH Intramural Sequencing Center
(NISC) as previously described [McLaughlin et al., 2010]. Each
HARS variant was independently confirmed via PCR amplifica-
tion followed by DNA sequencing analysis. Nucleotide positions are
relative to the open reading frame from GenBank Accession No.
NM_002109.3. Nucleotide numbering reflects cDNA position with
+1 corresponding to the A of the ATG translation initiation codon
in the reference sequence. Codon numbering for the HARS protein
was based on the reported amino acid sequence (NCBI accession
no. NP_002100.2). The initiation codon is codon 1. The variants
were submitted to an LSDB at www.LOVD.nl/HARS.
Control Sample Genotyping
A total of 576 DNA samples isolated from neurologically normal
controls were obtained from the National Institute of Neurolog-
ical Diseases and Stroke (NINDS) and Coriell Institute for Med-
ical Research (Panel numbers NDPT079, NDPT082, NDPT084,
NDPT090, NDPT093, and NDPT094) and genotyped for each
HARS variant using MassARRAYR© iPLEX Gold technology (Se-
quenom, San Diego, CA). Briefly, multiplex HARS-specific PCR
reactions were performed (primer sequences available upon re-
quest) followed by primer extension assays using mass-modified
dideoxynucleotide terminators. MALDI-TOF mass spectrometry
was used to determine the genotype for each individual us-
ing SpectroTYPER software (Sequenom). The presence of each
HARS variant in the general population was additionally assessed
using the Exome Variant Server (snp.gs.washington.edu/EVS/),
the 1000genomes database (www.1000genomes.org/), and dbSNP
(www.ncbi.nlm.nih.gov/snp).
Multispecies Comparative Sequence Analysis
HARS protein orthologs from multiple species were derived
from the following GenBank accession numbers: Human (Homo
sapiens, NP_002100.2), Mouse (Mus musculus, NP_032240.3),
Chicken (Gallus gallus, NP_001006144.1), Zebrafish (Danio rerio,
NP_001004586.1), Nematode (Caenorhabditis elegans,
NP_001023373.1), Fruit Fly (Drosophila melanogaster,
NP_728180.1), Baker’s Yeast (Saccharomyces cerevisiae,
AAA34696.1), and Bacteria (Escherichia coli,NP_289067.1). Amino
acid sequences were aligned using Clustal W2 (http://www.ebi.ac.
uk/Tools/clustalw2/index.html).
Computational Predictions of Pathogenicity
Each HARS protein variant was analyzed using the MUPro
(http://www.ics.uci.edu/∼baldig/mutation.html),PolyPhen(http://
genetics.bwh.harvard.edu/pph/index.html), PolyPhen2 (http://
genetics.bwh.harvard.edu/pph2/), and SIFT (http://sift.jcvi.org/
www/SIFT_seq_submit2.html) prediction algorithms.
Yeast Complementation Assays
DNAconstructs for yeast complementation assayswere generated
using Gateway cloning technology (Invitrogen, Carlsbad, CA). The
S. cerevisiae HTS1 locus (including the open reading frame and 477
base pairs of proximal promoter sequence) were PCR amplified us-
ing S. cerevisiae genomic DNA. Each primer was designed to include
flanking Gateway attB1 (forward) and attB2 (reverse) sequences
(primers available upon request). Subsequently, purified PCR prod-
ucts were recombined into the pDONR221 vector (according to the
manufacturer’s instructions) to yield an appropriate entry clone;
the insert of the final entry clone was sequenced to confirm speci-
ficity. Mutagenesis of HTS1 was performed using the QuikChange
II XL Site-Directed Mutagenesis Kit (Stratagene, Santa Clara, CA)
and appropriate mutation-bearing oligonucleotides. Subsequently,
plasmidDNApurified from each entry clonewas recombinedwith a
gateway-compatible pRS315 or pRS316 destination vector accord-
ing to the manufacturer’s instructions. Each resulting expression
construct was analyzed by restriction enzyme digestion with BsrGI
(New England Biosystems, Ipswich, MA) to confirm the presence of
an appropriately sized insert.
A commercially available diploid heterozygous hts1 yeast
strain (MATa/α, his31/his31, leu20/leu20, LYS2/lys20,
met150/MET15, ura30/ura30; Open Biosystems, Hunstville,
AL) was transformed with aURA3-bearing pRS316 vector contain-
ing wild-type HTS1 (see above). Lithium acetate transformations
were performed at 30◦C using 200 ng of plasmid DNA, as pre-
viously described [Green et al., 1999]. Transformation reactions
were grown on yeast medium lacking uracil. Subsequently, sporu-
lation and tetrad dissections were performed to obtain a haploid
hts1 strain that also contains the wild-type HTS1 pRS316 main-
tenance vector. Briefly, the transformed diploid hts1 strain was
patched twice onto presporulation plates (5% D-glucose [Fisher
Scientific, Hampton, NH], 3% nutrient broth [Becton, Dickinson
and Company, Franklin Lakes, NJ], 1% yeast extract [Acros Organ-
ics, Waltham, MA], and 2% agar [Teknova, Hollister, CA]). One
microliter of cells was then transferred into 2 ml of supplemented
liquid sporulation medium (1% potassium acetate [Fisher Scien-
tific], 0.005% zinc acetate [Fisher Scientific], 1X ura supplement
[MP Biomedicals, Solon, OH], 1X his supplement [MP Biomed-
icals], and 1X leu supplement [MP Biomedicals]) and incubated
for 5 days at 25◦C followed by 3 days at 30◦C. Sporulated strains
were dissected using a MSM 400 dissection microscope (Singer In-
struments, Somerset, UK), and plated on yeast extract, peptone, and
dextrose (YPD)plates (Becton,Dickinson andCompany). Resulting
spores were individually patched onto solid growth medium con-
taining Geneticin (G418) or 0.1% 5-fluoroorotic acid (5-FOA), or
media lacking uracil (Teknova). Two spores that grew on G418 and
yeast medium lacking uracil, yet did not grow on 5-FOA medium,
were selected for use in the yeast viability assays. Two resulting hap-
loid hts1 strains bearing a wild-type HTS1 pRS316 maintenance
vector were then transformed with LEU2-harboring pRS315 con-
structs containingwild-type ormutantHTS1 (described above) and
grown on medium lacking uracil and leucine (Teknova). For each
transformation, five colonies were selected for additional analysis.
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Each colony was diluted in 100 µl H2O, then further diluted 1:10
and 1:100, and spotted on growth medium containing 0.1% 5-FOA
(Teknova), incubated for 3 days at 30◦C, and growth was assessed
by visual inspection. Because 5-FOA is toxic to yeast cells bearing a
functionalURA3 allele, only cells that lost theURA3-bearing main-
tenance plasmid and for which the LEU2-harboring test plasmid
could complement the chromosomal hts1 allele were expected
to grow. To generate growth curves, surviving yeast colonies from
strains modeling p.Val238Ala and p.Pro505Ser HTS1 were inocu-
lated in selective medium and incubated shaking overnight at 30◦C.
Dilutions were generated in YPD medium to obtain an OD660 of
0.05, and cultures incubated shaking at 30◦C. The OD660 was then
measured at 1, 2, 3, 4, 5, 6, 7, and 25 hours using a NanoDrop 1000
(Thermo Fisher Scientific, Waltham, MA). The percent increase in
growthwas determined by dividing each of themeasuredOD660 val-
ues by the initialOD660 value and expressing relative to thewild-type
HTS1-harboring strain.
C. elegans Strains and Genetics
Standard methods for maintaining C. elegans were used [Bren-
ner, 1974]. Bristol strain N2 was used as the wild type, and all
animals were grown at 20◦C. All C. elegans strains were obtained
from the C. elegansGenetics Stock Center, University of Minnesota,
Minneapolis.
C. elegans Transgene Construction
C. elegans transgene constructs were made from the expression
vector pPD157.60 (Addgene, Firelab vector kit), which contains
promoter sequences from theC. elegans glutamic acid decarboxylase
(unc-25) gene. Expression of C. elegans wild-type or mutant hars-
1 cDNAs were engineered by cloning sequence verified full-length
wild typeormutantR137QcDNAsequences into theXbaI/NaeI sites
of pPD157.60. Green fluorescent protein (GFP) fusion constructs
were engineered using a PCR fusion approach to generate in-frame
N-terminal tagged Punc-25::GFP-hars-1 (WT or R137Q) plasmids
[Hobert, 2002].
Transgenic C. elegans Strain Construction
Transgenic C. elegans strains were generated by standard mi-
croinjection techniques [Mello et al., 1991]. All transgenic strains
were injected with plasmids of interest at 50 ng/ml + 2.5 ng/ml
pCFJ90 (Pmyo-2::mCherry) + 47.5 ng/ml 1 Kb+ DNA Ladder (In-
vitrogen). For all strains, stable transgenic lines were selected based
on mCherry expression in the pharyngeal muscles from a Pmyo-
2:mcherry coinjectionmarker. At least three independent lines were
isolated and analyzed. The data shown are from one representative
line.
Phenotypic Scoring in C. elegans
Movement defects were quantified by counting the number of
body thrashes in liquid for a 2-min interval [Miller et al., 1996].
Specifically, 100 µl of room temperature M9 media was aliquoted
into an agar-coated 96 well plate. Individual animals were picked to
wells and allowed to acclimate for 2 min. Movement was recorded
using a cooled monochrome camera (Leica) and the number of
times animals bent across their body axis was counted. To allow for
accurate scoring of body bends, the image sequence was played at
one-quarter speed offline using ImageJ. The total number of body
bends counted was divided by two, yielding a body thrash/minute
count.
Quantification of Neuronal Defects in C. elegans
Motor neuron quantification was performed on the following
strains: EG1285: oxIs12 (Punc-47::GFP; lin-15b) X, BEG9: oxIs12
(Punc-47::GFP, lin-15b) X; aabEx8 (Punc-25::hars-1 [WT], Pmyo-
3::mCherry), BEG10 : oxIs12 (Punc-47::GFP, lin-15b) X; aabEx9
(Punc-25::hars-1 [R137Q], Pmyo-3::mCherry), BEG11: aabEx10
(Punc-25::GFP-hars-1 [WT], Pmyo-3::mCherry), BEG12: aabEx11
(Punc-25::GFP-hars-1 [R137Q], Pmyo-3::mCherry). Synchronized
fourth larval stage worms were grown at 20◦C. L4, 1-day, and 4-
day adults were selected for imaging and phenotypic characteriza-
tion. To visualize axonal processes, transgenic worms were anes-
thetized in M9 buffer containing 5 mM levamisole, mounted on
agar pads and then coverslipped. To quantify the percent animals
exhibiting aberrant GABA motor neurons commissures, >100 ani-
mals/genotype/timepoint were imaged. Animals exhibiting at least
one aberrant commissure were scored as positive.
Microscopy
Animals were imaged on a Leica DMI6000B compound micro-
scope with a CCD camera (FDC360, Leica) using a 40X objective.
Confocal images were obtained on a Nikon A1R microscope with a
20X objective.
Results
Mutation Analysis of the HARS Locus
We screened the HARS gene for protein-coding variations in
363 patients with peripheral neuropathy and no previously iden-
tified mutation (the appropriate, institute-specific review boards
approved all studies performed herein, and informed consent was
obtained from all subjects). These efforts revealed six HARS mis-
sense variants in the heterozygous state in eight patients from our
cohort: c.14C>Awhichpredictsp.Ala5Glu, c.410G>Awhichpredicts
p.Arg137Gln, c.605G>A which predicts p.Gly205Asp, c.713T>C
whichpredicts p.Val238Ala, c.1127A>Gwhichpredicts p.Lys376Arg,
and c.1513C>T which predicts p.Pro505Ser (Table 1).
To determine the frequency of each identified HARS variant
we tested for the presence of each in five available resources: (1)
dbSNP (locus identifier 3035); (2) the NINDS/Coriell neurolog-
ically normal control panels (NDPT079, NDPT082, NDPT084,
NDPT090,NDPT093, andNDPT094); (3) theExomeVariant Server
(EVS; snp.gs.washington.edu/EVS/); (4) the 1000genomes database
(browser.1000genomes.org); and (5) the ClinSeqTM patient cohort
[Biesecker et al., 2009]. This revealed the presence of p.Ala5Glu,
p.Arg137Gln, p.Gly205Asp, and p.Lys376ArgHARS in one or more
of these analyses, whereas p.Val238Ala and p.Pro505SerHARS were
not detected in any of the five resources (Table 1). We also collected
DNA samples from additional affected and unaffected family mem-
bers related to the two carriers of p.Gly205AspHARS and the single
carrier of p.Lys376Arg HARS. Neither of these variants segregate
with disease status in the three pedigrees (data not shown). Addi-
tional family members were not available to test for segregation of
the remaining four variants with disease status.
To predict the pathogenic potential of the identified HARS vari-
ants we assessed the evolutionary conservation of each affected
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Table 1. Identification of HARS Variants in Patients with Peripheral Neuropathy
cDNA Amino acid Patient NINDS control EVS 1000genomes ClinSeqTM dbSNP accession
changea changeb chromosomes chromosomes chromosomes chromosomes chromosomes no.
c.14C>A p.Ala5Glu 2/726 10/1,066 86/10,670 8/2,188 9/1,130 rs78741041
c.410G>A p.Arg137Gln 1/726 0/1,088 1/10,757 1/2,188 1/1,148 rs191391414
c.605G>A p.Gly205Asp 2/726 3/1,022 15/10,743 7/2,188 2/1,146 rs147288996
c.713T>C p.Val238Ala 1/726 0/1,092 NP NP NP NP
c.1127A>G p.Lys376Arg 1/726 0/1,090 62/10,696 3/2,188 NP rs139447495
c.1513C>T p.Pro505Ser 1/726 0/1,088 NP NP NP NP
aNucleotide positions are relative to the open reading frame from GenBank Accession number NM_002109.3.
bAmino acid positions are relative to GenBank Accession number NP_002100.2.
NP, not present.
Table 2. Computational Predictions of HARS Variant Pathoge-
nicity
Variant MUProa PolyPhenb PolyPhen2c SIFTd
p.Ala5Glu 0.20 0.34 0.00 1.00
p.Arg137Gln –1.00e 2.46e 1.00e 0.00e
p.Gly205Asp 0.00 0.71 0.28 0.00e
p.Val238Ala –1.00e 1.90e 0.78 0.00e
p.Lys376Arg 0.48 1.41 0.01 0.31
p.Pro505Ser –.99e 2.01e 0.31 0.00e
aMUPro scores <0 indicate a decrease in protein stability.
bPolyPhen scores ≥1.5 indicate a prediction of “pathogenic.”
cPolyPhen2 scores ∼1 indicate a prediction of “pathogenic.”
dSIFT scores ≤0.05 indicate a prediction of “pathogenic.”
eDenotes a “pathogenic” prediction.
amino acid. Briefly, we collected the protein sequences of HARS
orthologs from multiple, evolutionarily diverse species, aligned the
sequences with ClustalW2 software [Larkin et al., 2007], and visu-
ally inspected each affected amino acid (Fig. 1B). Alanine 5 resides
in a region of the protein sequence that is difficult to align, and is
conserved among three of the five species analyzed. Arginine 137 is
conserved among all species analyzed, including bacteria—indeed,
this amino acid residue is invariant among all available protein se-
quences [Freist et al., 1999]. Glycine 205 is conserved among six of
the eight species analyzed, including worm and fruit fly. Valine 238
is conserved among seven of the eight species analyzed, including
yeast. Lysine 376 is conserved among four of the eight species an-
alyzed, all of which are vertebrate species. Finally, proline 505 also
resides in a region of the protein sequence that is difficult to align
and is conserved among two of the eight species analyzed.
We applied computational predictions to further assess the poten-
tial effect of eachHARSvariantonprotein functionusing theMuPro,
PolyPhen, PolyPhen2, and SIFT algorithms [Cheng et al., 2006]
(Table 2), which have been employed to assess disease-associated
ARS mutations [McLaughlin et al., 2010]. The HARS variants
p.Ala5Glu and p.Lys376Arg were not predicted to be pathogenic
by any of the algorithms, and p.Gly205Asp was only predicted to be
pathogenic by one of the four algorithms. In contrast, p.Val238Ala
and p.Pro505Ser were predicted to be pathogenic by three of the
four algorithms, and p.Arg137Gln was predicted to be pathogenic
by all four algorithms employed.
We next mapped each variant onto the primary structure of the
HARS protein (Fig. 1C). Alanine 5 is located at the first amino acid
of the WHEP-TRS domain, which is predicted to mediate the as-
sociation of HARS with the multiple ARS complex (pfam00458 in
the NCBI Conserved Domain Database). Interestingly, glycyl-tRNA
synthetase (GARS) has a similar N-terminal domain [Antonellis
et al., 2003] and, to date, no disease-associated mutations have been
identified therein. Arginine 137, glycine 205, valine 238, and lysine
Table 3. Human HARS Variants Modeled in the Yeast Ortholog
HTS1
Human HARSa Yeast HTS1b
p.Arg137Gln p.Arg116Gln
p.Gly205Asp p.Lys184Asp
p.Val238Ala p.Val217Ala
p.Lys376Arg p.Lys371Arg
p.Pro505Ser p.Val519Ser
aAmino acid coordinates correspond to GenBank accession number NP_002100.2.
bAmino acid coordinates correspond to GenBank accession number AAA34696.1.
376 reside within the catalytic core of the enzyme and proline 505
resides within the tRNA-binding domain (Fig. 1C). Thus, the vari-
ants that affect these amino acids may be detrimental to enzyme
kinetics or tRNA recognition. Importantly, previously described
disease-associated ARS mutations impair these two processes [An-
tonellis and Green, 2008; Antonellis et al., 2006; Latour et al., 2010;
McLaughlin et al., 2010, 2012; Nangle et al., 2007].
p.Arg137Gln HARS Represents a Loss-of-Function Allele
In Vivo
Yeast complementation assays have been successfully employed
to evaluate the functional consequences ofGARS, YARS, AARS, and
KARS mutations. [Antonellis et al., 2006; Jordanova et al., 2006;
McLaughlin et al., 2010, 2012]. Importantly, each ARS allele that is
unable to complement deletion of the yeast ortholog is also unable
to charge tRNA molecules as assessed by in vitro aminoacylation
assays indicating that yeast is a relevant in vivo model to test for a
loss-of-function effect [Antonellis et al., 2006; Jordanova et al., 2006;
McLaughlin et al., 2010, 2012; Nangle et al., 2007]. To experimen-
tally evaluate p.Arg137Gln, p.Gly205Asp, p.Val238Ala, p.Lys376Arg,
and p.Pro505SerHARS for a loss-of-function effect in vivo, wemod-
eled the missense changes in the yeast orthologHTS1 (Table 3) and
tested the ability of each variant to support yeast cell growth in
complementation assays—p.Ala5Glu HARS was not modeled due
to the inability to predict the orthologous residue in yeast (Fig. 1B).
Briefly, a haploid yeast strain was generated with the endogenous
HTS1 gene deleted (hts1) and viability supported via a mainte-
nance vector consisting of a wild-type copy of HTS1 on a URA3-
bearing plasmid (pRS316). Experimental alleles were generated on a
LEU2-bearing vector (pRS315), transformed into the above strain,
and viability assessed by analysis of growth on 5-fluoroorotic acid
(5-FOA), which selects for spontaneous loss of the URA3-bearing
maintenance vector [Boeke et al., 1984]. The wild-type HTS1 vec-
tor supported significant growth, while an insert-free pRS315 con-
struct did not (Fig. 2A), consistent with our experimental vector
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Control
Patient
Control
Patient
A
B
C
p.Val238Ala
p.Gly205Asp
p.Arg137Glnp.Ala5Glu p.Lys376Arg p.Pro505Ser
5 49 69 394 408 507
Catalytic WHEP-TRS tRNA Binding
Human
Mouse
Chicken
Zebrafish
Nematode
Fruit Fly
Baker’s Yeast
Bacteria
p.Ala5Glu
AERAALE
ADRAALE
AD----E
SMRLCAG
ERKAILM
DTREQIL
------M
-------
p.Arg137Gln
PFARYLA
PFARYLA
PFARYLA
PFARYLA
PFARYLA
PLARYLA
PFARYVA
GCVRAGI
p.Gly205Asp
LQIGDFL
LQIGNFL
LQLGDFL
LDLGDFR
LEIGEFF
LDIGDYV
LGIKDFK
LGISEHV
p.Val238Ala
CSSVDKL
CSSVDKL
CSSVDKL
CSTVDKL
CSSVDKL
CSAVDKL
SSAVDKL
EQHKEKL
p.Lys376Arg
KGRKVPC
KGRKVPC
KGRKVPC
KAGKCPV
KAN-VPC
RGKAVPC
-GKK---
-GRATPA
p.Pro505Ser
TGQPLCI
TNQPLST
TNQL---
-------
LAAL---
QQASA--
LNEVTRL
LG-----
p.Arg137Gln
G A
p.Val238Ala
T C
C A
p.Ala5Glu
A G
p.Lys376Arg
C T
p.Pro505Ser
G A
p.Gly205Asp
Figure 1. Identification, conservation, and localization of HARS variants. A: Representative sequence chromatograms are shown for the regions
encompassing each identified HARS variant. Arrows indicate the position of each variant (present in the heterozygous state), with the nucleotide
changes shown below and the predicted amino acid changes depicted above. B: Multiple-species protein alignments were generated to assess
the conservation of affected amino acid residues. For each of the detected variants, the affected amino acid is shown along with the flanking HARS
protein sequence in multiple, evolutionarily diverse species (indicated on the left). Note that the amino acid change is provided at the top, with
conservation indicated in red for each protein sequence. C: HARS variants were mapped to the known functional domains of the protein, indicated
in green (WHEP-TRS), red (catalytic domain), and blue (tRNA binding domain). The position of each domain along the protein is indicated below
the cartoon.
harboring a functional copyofHTS1, andwithHTS1being an essen-
tial gene, respectively. The p.Gly205Asp, p.Val238Ala, p.Lys376Arg,
and p.Pro505Ser HTS1 variants allowed growth in a manner con-
sistent with wild-type HTS1. Because p.Val238Ala and p.Pro505Ser
HARS were not detected in the public variant databases (Table 1),
we further explored them for a loss of function via growth curve
analysis. Neither of these variants grew in a manner significantly
different from wild-type HTS1 over a 25-hr period (Fig. 2B). In
contrast to the above results, p.Arg137GlnHTS1 could not comple-
ment the hts1 allele (Fig. 2A). Combined, our functional and com-
putational analyses strongly suggest that p.Arg137Gln represents a
loss-of-function allele and that it is the most likely of the HARS
variants to be pathogenic. This notion is based on observations
that previously identified disease-associated ARS mutations occur
at highly conserved amino acids, are computationally predicted to
be pathogenic, and cause a loss of function in aminoacylation and
yeast growth assays [Antonellis et al., 2003, 2006; Jordanova et al.,
2006; Latour et al., 2010; McLaughlin et al., 2010, 2012; Nangle
et al., 2007].
Clinical Evaluation of Patients Carrying the p.Arg137Gln
HARS Allele
The p.Arg137Gln HARS variant was identified in a patient with
sporadic motor and sensory peripheral neuropathy, with sensory
deficits more severe than motor deficits. At examination, the pa-
tient was a 64-year-old male with a 15-year history of impaired
sensation in the lower extremities. There was no history of pain-
less ulcers and he suffered from shooting pains in his legs over the
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Figure 2. Growth of yeast strains expressing wild-type and mutant
HTS1. A: Representative cultures of each yeast strain (indicated along
the top of the panel) were inoculated and grown on solid growthmedium
containing 5-FOA at the indicated culture dilutions (1:1, 1:10, or 1:100).
Each strain was previously transfected with a vector containing no in-
sert (“pRS315”), wild-type HTS1, or the indicated mutant form of HTS1
that modeled a human HARS mutation (see text). Identical results were
obtained using two hts1 haploid yeast strains and three indepen-
dently generated sets of HTS1 expression constructs (data not shown).
B: Growth curve analysis of HTS1 variants. Yeast cultures were grown
in SDmedia lacking leucine over 25 hr and the OD660 wasmonitored. The
mean values obtained from three replicates of yeast cell growth asso-
ciated with variant HTS1 are expressed as a ratio to the growth of three
replicates of wild-type HTS1. Error bars indicate standard deviation.
previous 4 years. Pes cavus and hammer toes were absent and there
was no overt muscle wasting. There were brisk knee jerks, absent
ankle jerks, and the plantar reflexes were flexor. Previous nerve con-
duction studies at age 57 showed a mild slowing of peroneal motor
conduction velocity at 37 m/sec with a distal latency of 6.6 m/sec
and an amplitude of 5.60 microvolts, and a sural sensory ampli-
tude of 6.5 uV. At age 64, there were absent sural responses and
a borderline reduced (10 uV) and delayed (3.82 m/sec) median
sensory action potential. The peroneal motor action potential was
not obtained and the median motor conduction velocity was 50
m/sec. Combined, these data indicate a neuropathy of axonal (or
mixed axonal and demyelinating) origin. Interestingly, neurological
examination of the 57 year-old female ClinSeqTM subject who is a
carrier of p.Arg137Gln HARS (Table 1) did not reveal peripheral
neuropathy—Sanger sequencing confirmed that this individual in-
deed carries this variant (data not shown). Given the late age of
disease onset in the original patient and the incomplete penetrance
of certain neuropathy-associated ARS mutations [Dubourg et al.,
2006; Sivakumar et al., 2005], determining the pathogenic poten-
tial of p.Arg137Gln HARS in a relevant animal model system was
considered essential for confirming the pathogenicity.
p.Arg137Gln HARS is Toxic to Neurons In Vivo
To evaluate the neurotoxicity of p.Arg137GlnHARS, we used the
genetically tractable soil nematode, C. elegans, as an experimental
model. As in humans, the C. elegans genome contains a single gene
encoding cytoplasmic HARS (hars-1). The C. elegans HARS-1 pro-
tein is 54% identical and 70% similar to the human ortholog HARS
(data not shown). Due to the conservation of arginine 137 between
human and worm (Fig. 1B), we hypothesized that C. elegans hars-1
might be used as a template to screen and differentiate mutations
that impart neuronal toxicity in vivo. To this end, we overexpressed
C. elegans hars-1 variants specifically in GABAergic neurons, most
of which are subclasses of motor neurons in nematode, to deter-
mine if p.Arg137Gln is sufficient to cause functional motor neuron
defects. To engineer the GABA motor neuron specific expression
of HARS-1 in C. elegans, a chimeric transgene was constructed in
which the promoter region of the C. elegans unc-25 gene, which
encodes for glutamic acid decarboxylase, directs the expression of a
full-length wild-type or p.Arg137Gln hars-1 cDNA (Punc-25::hars-
1 [WT] or Punc-25::hars-1 [p.Arg137Gln]) [Schuske et al., 2004].
To assay motor neuron abnormalities associated with transgene ex-
pression, the Punc-25::hars-1 (WT or p.Arg137Gln) transgene was
introduced into an integrated strain containing the oxIs12 reporter
transgene [McIntire et al., 1997], which expresses GFP under the
control of theGABAmotor neuron specific unc-47 promoter [Punc-
47::GFP] (Fig. 3A and B). This strain allows for the visualization of
all GABA motor neuron cell bodies and their fine axonal processes
(Fig. 3B). Motor neuron specific expression of p.Arg137Gln, but
not WT, induced significant morphological abnormalities in GABA
motor neurons (Fig. 3C and D). Expression of the p.Arg137Gln
variant resulted in aberrant commissural axonal processes in∼40%
of animals analyzed at three different developmental stages (L4, 1-
day adult, and 4-day adult; Fig. 3G). Specifically, animals bearing
the p.Arg137Gln transgene exhibited gross morphological defects
in commissural axons, denoted by failure to reach the dorsal nerve
cord, axonal beading, defasiculation, and breaks in the visualized
GABAergic dorsal nerve cord (Fig. 3D). None of these defects were
observed in transgenic control animals or animals over-expressing
a wild-type transgene (Fig. 3B and C).
To determine if the morphological aberrations observed in the
p.Arg137Gln transgenic animals were due to mislocalization of the
HARS-1 protein, we constructed wild-type and p.Arg137Gln GFP
fusion proteins directed by the unc-25 promoter (Punc-25::GFP-
hars-1 [WT] or Punc-25::GFP-hars-1 [p.Arg137Gln]). Heritable
transgenic strains were generated by microinjection into N2 wild-
type C. elegans strains [Mello and Fire, 1995; Mello et al., 1991].
Both the wild-type and p.Arg137Gln GFP fusion proteins localized
specifically to GABA motor neurons and GFP was observed in the
cell bodies and axonal processes (Fig. 3E and F). Importantly, the
GFP-p.Arg137Gln fusion protein was able to recapitulate many of
the axonal defects observed in transgenic animals overexpressing
the nontagged p.Arg137Gln variant (Fig. 3F)—these defects were
not seen in animals expressing the wild-type HARS-1 GFP fusion
protein (Fig. 3E).
Lastly, we tested whether GABA neuron-specific expression of
hars-1 transgenes could induce motor performance defects. In
addition to aberrant commissural axonal processes, p.Arg137Gln
transgenic animals displayed mild locomotor defects on agar plates,
whereas wild-type expressing strains appeared normal (data not
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Figure 3. Neurotoxic effect of p.Arg137Gln (R137Q) hars-1 expression in C. elegans motor neurons. A: Schematic diagram of the DD and VD
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Specific expression of mutant HARS-1 (R137Q) in GABAmotor neurons results in abnormal commissural axonal phenotypes, denoted by prominent
axonal beading (arrowheads) and thinning of the dorsal nerve cord (arrow). E: Expression of a wild-type GFP-HARS-1 (WT) fusion protein in GABA
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movement defects. Mutant HARS-1(R137Q) expressing animals exhibit a progressive loss of motor coordination. (error bars ± S.E.M., ∗P < 0.005, n
= 10/genotype).
shown). These defects were more severe in liquid media where
thrashing rates [Miller et al., 1996] of p.Arg137Gln transgenics
were significantly lower than the control or wild-type expressing
strains (Fig. 3H). Interestingly, the aberrant axonal phenotype was
present at L4 through 4-day adults, but the functional defect only
manifests in 4-day adults (Fig. 3H). These data suggest that the
p.Arg137Gln mutant exhibits a progressive loss of motor neuron
function and coordination. Taken together, the in vivo morpholog-
ical and functional defects suggest that p.Arg137GlnHARS imparts
a cell autonomous neurotoxicity to motor neurons.
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Discussion
Here, we describe mutation analysis of theHARS gene in patients
with peripheral neuropathy. Six missense variants were identified
and characterized, and computational and functional analyses re-
vealed the following features of the p.Arg137Gln HARS variant: (1)
location within the catalytic domain of the HARS protein and at
an amino-acid residue conserved between human and bacteria; (2)
loss-of-function based on yeast complementation assays; and (3)
dominant toxicity to neurons in a C. elegans model. Importantly,
we have recently validated the C. elegansmodel of neurotoxicity via
analysis of themost commonneuropathy-associated ARSmutation,
R329H alanyl-tRNA synthetase ([AARS]; A.A. Beg, personal com-
munication, 2011). Combined, these data indicate that p.Arg137Gln
HARSmay be a pathogenic allele similar to other disease-associated
ARS mutations—such mutations are found in patients with motor
and sensory peripheral neuropathy and an axonal pathology, cause
a loss of function in tRNA charging, yeast viability, or proper local-
ization within axons, and are dominantly toxic to axons in animal
model systems [Antonellis et al., 2003, 2006; Jordanova et al., 2006;
Latour et al., 2010;McLaughlin et al., 2010, 2012;Nangle et al., 2007;
Seburn et al., 2006; Storkebaum et al., 2009]. Furthermore, arginine
137 resides in the BM12 domain of the HARS protein, which is
involved in enzyme dimerization [Freist et al., 1999]—the majority
of disease-associated GARS mutations also affect amino acids that
reside on the dimer interface [Cader et al., 2007; He et al., 2011;
Nangle et al., 2007; Xie et al., 2007]. Our findings expand the panel
of loss-of-function human ARS alleles, and the data from our worm
experiments indicate that p.Arg137GlnHARS is toxic to neurons in
vivo.
Themechanistic link between heterozygosity for loss-of-function
ARS alleles and axonal degeneration remains unknown. Haploin-
sufficiency of tRNA charging seems an unlikely explanation based
on data showing that most disease-associated mutations are mis-
sense changes and that heterozygosity for a Gars null allele does
not cause neuropathy in mouse [Seburn et al., 2006]. One possi-
bility is that mutant ARS monomers interfere with the activity of
the wild-type protein by a dominant-negative effect. This is con-
sistent with the observation that all ARS enzymes implicated in
axonal degeneration to date act as oligomers—HARS functions as
a homodimer [Freist et al., 1999] and p.Arg137Gln does not affect
enzyme dimerization (data not shown). This possibility is further
supported by the identification of compound heterozygosity for a
null allele and a hypomorphic allele at the lysyl-tRNA synthetase
(KARS) locus in a patient with peripheral neuropathy [McLaughlin
et al., 2010]. The combination of these alleles is predicted to cause
a depletion of KARS activity below 50% and to possibly cross a
threshold of tRNA charging required for axon function. However,
overexpression of wild-type human GARS in two mouse models of
dominant peripheral neuropathy caused by heterozygosity for Gars
mutations did not dramatically improve the phenotype [Motley et
al., 2011], indicating that any dominant-negative effect may be ir-
reversible. However, it will be important to determine if wild-type
HARS-1 can complement the toxicity of p.Arg137Gln HARS-1 in
a stable transgenic C. elegans model system using Mos1-mediated
transgenesis. Another possibility is that impaired tRNA charging
or impaired ARS localization are prerequisites for some undefined
gain-of-function toxicity to axons (e.g., these RNA-binding proteins
may now be free to inappropriately interact with RNA molecules
in the axon or nerve cell body). Finally, the neurotoxic effect of
ARS mutations is unlikely to involve mitochondrial enzyme func-
tion. AlthoughGARS andKARS charge tRNA in both the cytoplasm
and mitochondria, YARS, AARS, and HARS are predicted to charge
tRNA only in the cytoplasm. Furthermore, disease-associated mu-
tations in the genes encoding mitochondrial ARS enzymes (AARS2,
DARS2, EARS2, HARS2, MARS2, RARS2, SARS2, and YARS2) are
not associated with an overt axonal neuropathy [Bayat et al. 2012;
Belostotsky et al. 2011; Edvardson et al., 2007; Gotz et al. 2011;
Pierce et al. 2011; Riley et al. 2010; Scheper et al., 2007; Steenweg et
al. 2012]; however, detailed neurological examinations of patients
withmitochondrial ARSmutations will be required to rule out such
a phenotype.
Inherited peripheral neuropathies are clinically and genetically
heterogenous with variable age of onset and reduced penetrance
associated with specific loci. Moreover, the extent to which genetic
(i.e., due to inherited or de novo mutations) versus environmental
causes (e.g., diabetes and vitamin deficiencies) account for the 10%
prevalence of peripheral neuropathy in the aging population [Mar-
tyn and Hughes, 1997] is unknown. As such, these diseases present
a major challenge for the identification and validation of disease-
causing or disease-modifying variants, especially when faced with
small pedigrees or sporadic cases with one or both biological par-
ents unavailable to evaluate for de novo mutations, thus hindering
the ability to build a robust genetic argument. Indeed, the identi-
fication of p.Arg137Gln HARS in one affected and one unaffected
individual underscores the importance of informative functional
analyses. The studies outlined here have two major implications for
the above challenges. First, we present a pipeline to rapidly assess
ARS alleles for impaired function and axonal toxicity in vivo. This
approach will aid in the distinction between pathogenic and non-
pathogenic ARS alleles and is feasible for variants identified at all
37 human ARS loci [Antonellis and Green, 2008]. Second, these
findings underscore the importance of identifying ARS alleles with
neurotoxic potential in patient cohorts or in the general population.
Alleles such as p.Arg137GlnHARSmay directly predispose patients
to peripheral neuropathy or may modify a peripheral neuropathy
phenotype by contributing to the genetic and environmental load
[Lupski et al., 2011] in a given patient. However, although our func-
tional analyses revealed a loss-of-function neurotoxic HARS allele,
the causal link betweenHARSmutations and peripheral neuropathy
remains unclear, largely due to the lack of a strong genetic argument.
Studies designed to further screen relevant patient populations for
HARS mutations, clinically evaluate other carriers of p.Arg137Gln
HARS, and develop amammalianmodel of p.Arg137GlnHARSwill
be critical for addressing this issue. In summary, our approaches
and findings have important implications for understanding ARS
variants and how they relate to human disease as well as a basis
for understanding such variation in the context of gene–gene and
gene–environment interactions.
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